Susan Charman is Director of the Centre for Drug Candidate Optimisation and Professor at the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University. Her research is focused on relating basic physicochemical properties of new drug candidates to their absorption, distribution, metabolism and elimination properties that underpin pharmacokinetic (PK) disposition. Optimisation of PK properties is essential for new drug candidates to ensure safe and efficacious exposure profiles and convenient dosing regimens. Her research group has established robust industry-standard platforms to assess physicochemical, permeation, and protein binding properties, to profile metabolic stability and identify potential metabolites, to assess the potential for metabolic drug interactions, to characterize oral bioavailability and pharmacokinetic properties, and to establish clearance mechanisms. She has extensive experience working in multidisciplinary drug discovery teams, particularly in the area of tropical infectious diseases, and has supported drug discovery activities of the Medicines for Malaria Venture for nearly 20 years. She led the PK activities for discovery projects that led to one approved antimalarial drug (Synriam™), three antimalarial compounds currently in Phase 2 clinical trials, two in Phase 1, and another two currently undergoing preclinical testing. She has also collaborated extensively with the Australian Biotech industry and her research group has contributed to lead optimisation programs that have progressed 32 new drug candidates to human clinical trials for a range of different indications.